This study is currently not recruiting participants.

Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Investigating the Effectiveness of Chemotherapy and Radiation Therapy in Treating Cervical Cancer (cancer of the cervix)

Not Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to determine if weekly chemotherapy with cisplatin and simultaneous radiation therapy increases the time of living disease-free compared to radiation therapy alone.

Detailed description of study

The purpose of this study is to determine if post-operative adjuvant chemo-radiation therapy (CRT) can significantly improve recurrence-free survival (RFS) when compared to radiation therapy (RT) alone in stage I-IIA cervical cancer patients with intermediate-risk factors after treatment with radical hysterectomy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cervical Cancer
  • Age: 18 years - 100 years
  • Gender: Female

The purpose of this study is to determine if weekly chemotherapy with an investigational medication and simultaneous radiation therapy increases the time of living disease-free compared to radiation therapy alone. This study focuses on patients with cervical cancer, a type of cancer that occurs in the cells of the cervix, which is the lower part of the uterus that connects to the vagina.

In this study, participants will undergo procedures that include receiving weekly chemotherapy along with radiation therapy. Chemotherapy involves the use of drugs to destroy cancer cells, while radiation therapy uses high-energy rays to target and kill cancer cells. The study will compare these procedures to receiving only radiation therapy.

  • Who can participate: This study is for patients with stage I-IIA cervical cancer who have intermediate-risk factors after undergoing radical hysterectomy.
  • Study details: Participants will receive either weekly chemotherapy with an investigational medication and radiation therapy or radiation therapy alone. A placebo will not be used in this study.
Updated on 19 Feb 2024. Study ID: 1105005598 (GOG-0263)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team